Image
Webinar

The Clinical Practice and Noridian Reimbursement Landscape of iStent infinite®

Standalone Surgery

Jul 29, 2024 | 7:00 PM PT

Faculty

Image

Dr. Billy Pan

Description:


Join us for an interactive webinar discussion on the future of glaucoma management! This informational webinar will focus on the Interventional Glaucoma Revolution, standalone iStent infinite surgery and procedure reimbursement landscape.

Agenda


  • Introduction
  • Interventional Glaucoma Revolution
  • Standalone iStent infinite®
  • Intermission
  • iStent infinite® Reimbursement
  • Q&A and Closing Remarks

  • Registration

    Error: Please enter your first name.
    Error: Please enter your last name.
    This field is required.
    This field is required.
    This field is required.
    This field is required.
    This field is required.
    Error: Your city is required.
    This field is required.
    Error: Your country is required.
    This Webinar is intended for residents within the targeted Noridian MAC reimbursement area.
    By checking this box, you confirm that you are at least 18 years-old and agree to BMC’s Privacy Policy. By providing your personal information, you agree to allow BMC and its affiliates to use this information to communicate with you in the future, including information about products, services, events and programs. Bryn Mawr Communications will use your information in accordance with BMC's Privacy Policy.
    Standard Compensation Language

    Dr. Pan is being compensated for his participation.

    INDICATION FOR USE. The iStent infinite® Trabecular Micro-Bypass System Model iS3 is an implantable device intended to reduce the intraocular pressure (IOP) of the eye. It is indicated for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed.

    CONTRAINDICATIONS. The iStent infinite is contraindicated in eyes with angle-closure glaucoma where the angle has not been surgically opened, acute traumatic, malignant, active uveitic, or active neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

    WARNINGS. Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization that could lead to improper placement of the stent and pose a hazard.

    MRI INFORMATION. The iStent infinite is MRConditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.

    PRECAUTIONS.The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 participants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic.

    ADVERSE EVENTS.The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%). CAUTION: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.
    Webinar: The Clinical Practice and Noridian Reimbursement Landscape of iStent infinite® Standalone Surgery by Avenue Live